Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

[1]  David A. Green,et al.  Predictors of cancer‐specific mortality after disease recurrence following radical cystectomy , 2013, BJU international.

[2]  E. Plimack,et al.  Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Schwartz,et al.  Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. , 2012, The Lancet. Oncology.

[4]  Anirban P. Mitra,et al.  Factors influencing post‐recurrence survival in bladder cancer following radical cystectomy , 2012, BJU international.

[5]  P. Kantoff,et al.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Kattan,et al.  How to tell if a new marker improves prediction. , 2011, European urology.

[7]  G. Sonpavde,et al.  Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Millward,et al.  MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Fimmers,et al.  Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  G. Sonpavde,et al.  Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. , 2010, The Lancet. Oncology.

[11]  G. Sonpavde,et al.  Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Tangen,et al.  Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium , 2010, BJU international.

[14]  S. Culine,et al.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  David C. Smith,et al.  Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma , 2009, Cancer.

[16]  C. Ryan,et al.  Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. , 2008, Clinical genitourinary cancer.

[17]  M. Galsky,et al.  Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma , 2007, Investigational New Drugs.

[18]  S. Culine,et al.  A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.

[19]  C. Sternberg,et al.  Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy , 2001, Cancer.